Drug intelligence / Profile preview

SBC114

Development stage: Preclinical
Lead developer: SapiensBio
Modality: Small Molecules

Overview

SBC114 is a small molecule drug candidate currently in preclinical development by SapiensBio for the treatment of fibrotic diseases. Discovered using the company's proprietary AI/ML-based SAPIENTIA platform, SBC114 is designed to modulate a novel, undisclosed biological target involved in the pathogenesis of fibrosis. The program is currently in the lead optimization phase, where compounds are being refined to achieve candidate compound grade for further advancement into IND-enabling studies.

Beyond the preview

Go deeper on SBC114.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBC114.

Explore the full profile